Recalls and alerts more than 4 years old are automatically archived. While this information can still be accessed in the database, it has not been altered or updated since it was archived. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats by contacting us.
PEGETRON REDIPEN (peginterferon alfa-2b) – Recall of Triad Group Alcohol Prep Pads, Alcohol Swabs, and Alcohol Swabsticks – For the Public
- Starting date:
- February 3, 2011
- Posting date:
- February 3, 2011
- Type of communication:
- Public Communication
- Source of recall:
- Health Canada
- General Public
- Identification number:
This is duplicated text of a letter from Merck Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.
Health Canada Endorsed Important Safety Information on PEGETRON REDIPEN (peginterferon alfa-2b)
February 3, 2011
Subject: Important information regarding PEGETRON® REDIPEN® (peginterferon alfa-2b Powder for Solution in Single Dose Delivery System: 80 mcg per 0.5 mL, 100 mcg per 0.5 mL, 120 mcg per 0.5 mL and 150 mcg per 0.5 mL)
Merck Canada Inc., in consultation with Health Canada, would like to inform you of important information regarding the use of PEGETRON® REDIPEN®. The alcohol prep pads that are included in your package of PEGETRON® REDIPEN® have been voluntarily recalled by the manufacturer, the Triad Group, due to potential microbial contamination. The alcohol swabs are labelled ALCO-PREP® Pre-injection cleansing swab.
- You should continue to use your PEGETRON® REDIPEN® injection and capsules as directed by your health care professional.
- Do NOT use the ALCO-PREP® Pre-injection cleansing swab, that are in your package of PEGETRON® REDIPEN®.
- Alternate alcohol pads are available for purchase at your local pharmacy or you can use sterile gauze pads with bottled isopropyl alcohol (70%).
- You are requested to report signs of injection site infections (such as redness, warmth, pain and/or swelling) to your healthcare professional.
Upon discussion and agreement with Health Canada, Merck Canada Inc. will begin packaging orders with suitable alternative alcohol prep pads.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious or unexpected adverse reactions in patients using PEGETRON® should be reported to Merck Pharmacovigilance or Health Canada as follows.
Merck Canada Inc., Pharmacovigilance
16711 Trans-Canada Hwy.
Kirkland, Quebec H9H 3L1
You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following three ways:
- Report online at MedEffectTM Canada
- Call toll-free at 1-866-234-2345
Complete a Reporting Form and:
- Fax toll-free to 1-866-678-6789, or
Mail to: Canada Vigilance Program
Postal Locator 0701E
Ottawa, Ontario K1A 0K9
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section.
For other health product inquiries related to this communication, please contact Health Canada at:
Health Product and Food Branch Inspectorate (HPFBI)
If you have any questions regarding this important information, please contact our Customer Services at 1-800-361-6550. For medical inquiries, please contact us at 1-800-567-2594.
original signed by
Michel Cimon, MD, MPH
Medical Executive Director, Medical Affairs
PEGETRON® Registered trademark of Schering-Plough Canada Ltd. Used under license.
REDIPEN® Registered trademark of Merck Canada Inc.
ALCO-PREP® : property of the owner.
- Date modified: